Bolt Biotherapeutics, Inc. (BOLT) News & EventsBOLTBolt Biotherapeutics, Inc.

Bolt Biotherapeutics Acquires Prana Therapies

Bolt Biotherapeutics announced the acquisition of Prana Therapies. Following the acquisition, the company will focus on advancing Prana's pipeline of half-life-extended multispecific antibodies generated from its proprietary INSPIRE platform, led by PRA-216, a novel IL-4Ralpha/TSLP bispecific antibody currently in Phase 2 development in asthma, chronic obstructive pulmonary disease, or COPD, and atopic dermatitis, with a Phase 2 study in eosinophilic esophagitis, or EoE, planned. The acquisition was structured as a sign-and-close reverse merger, in which the parties entered into a merger agreement for a stock-for-stock transaction. Concurrent with the acquisition, Bolt entered into a securities purchase agreement for a private placement financing, which includes $120M in upfront gross proceeds for the purchase of shares of Series D non-voting convertible preferred stock and up to an additional $60M upon exercise of accompanying warrants with a syndicate of new and existing leading healthcare institutional investors, including Deep Track Capital, ADAR1 Capital, Andreessen Horowitz, LYFE Capital, Coastlands Capital, Eventide Asset Management, Casdin Capital, Curie.Bio, SilverArc Capital, Soleus Capital, Deviation Capital and other institutional investors. The proceeds from the private placement are expected to fund operations into 2028 and through multiple anticipated clinical and preclinical milestones.

BDC-4182 Reports Q2 Revenue of $5,000

Reports Q2 revenue $5,000, consensus $500,000. "In the second quarter, we continued to make meaningful progress in the ongoing BDC-4182 Phase 1/2 study in patients with gastric and gastroesophageal cancer. We are currently treating patients in Cohort 4. To date, BDC-4182 has been well tolerated, and we are seeing activity consistent with our immune-stimulating mechanism," said Willie Quinn, President and Chief Executive Officer. "We expect to report initial clinical data from BDC-4182 with our third quarter 2026 results."

BDC-4182 Reports Q4 Revenue of $2.5M, Exceeding Expectations

Reports Q4 revenue $2.5M, consensus $857,250. "BDC-4182 is the first of our next-generation Boltbody ISACs to enter the clinic, and we saw a clear difference versus our first-gen ISACs in terms of immune response from the very first patient treated," said Willie Quinn, president and CEO. "The ISAC mechanism is radically different from ADCs and T cell engagers, and we believe that demonstrating anti-tumor activity with BDC-4182 will unlock an entirely new approach to treating cancer. We continue to enroll patients with gastric and gastroesophageal cancers in the Phase 1 dose-escalation trial and remain on track to report initial data in the third quarter of 2026."